BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia. It also provides CardiALLO, an allogeneic mesenchymal stem cell therapy which is in phase II for ischemic heart failure; allogeneic cell therapy platform; and PulmALLO, an allogeneic mesenchymal stem cell therapy for acute respiratory distress syndrome. In addition, the company offers the Helix biotherapeutic delivery system for minimally invasive targeted delivery of biologic agents to the heart; Heart3D for fusion imaging; and morph DNA and avance steerable introducers. It has a license and distribution agreement with Biomet Biologics, LLC. BioCardia, Inc. is based in Sunnyvale, California.…
BioCardia (BCDA) Upgraded to Buy: Here's What You Should Know
BioCardia (NASDAQ: BCDA) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 17 employees.
The shares were at 0.7850 USD on 20 November 2026, down 39.6% over 52 weeks. Its 52-week range is 0.6610 USD to 1.800 USD: the price is 56.4% below the high and 18.8% above the low.
Its market capitalisation is 11.88M USD.
BioCardia reports an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 3.82M USD. Its Piotroski F-score is 2 out of 9, a weak reading of its financial health.